Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652563 | 0.88 | QDPR (0.55) | QDPRADAM17ADAMTS5PDE4B | |
| SCHEMBL13362111 | 0.88 | QDPR (0.55) | QDPRADAM17ADAMTS5PDE4B | |
| SCHEMBL17197281 | 0.85 | QDPR (0.52) | QDPRADAM17ADAMTS5PDE4B | |
| SCHEMBL15651086 | 0.85 | QDPR (0.52) | QDPRADAM17ADAMTS5PDE4BTLR9 | |
| SCHEMBL2227613 | 0.84 | QDPR (0.59) | QDPRPDE4B | |
| SCHEMBL3311407 | 0.84 | QDPR (0.74) | QDPRPDE4BTLR7 | |
| SCHEMBL17076795 | 0.81 | QDPR (0.55) | QDPRADAM17ADAMTS5PDE4B | |
| SCHEMBL15651488 | 0.81 | QDPR (0.55) | QDPRADAM17ADAMTS5PDE4B | |
| SCHEMBL15653074 | 0.81 | QDPR (0.55) | QDPRADAM17ADAMTS5PDE4B | |
| SCHEMBL520850 | 0.80 | MEN1 (0.50) | QDPRPDE4BTLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | QDPR 807/4885CHEK1 1646/4885ADAM17 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.